Navigation Links
Simcere's Iremod Receives SFDA New Drug Approval
Date:8/25/2011

NANJING, China, Aug. 25, 2011 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it has received the new drug approval from the State Food and Drug Administration ("SFDA") for Iremod.

Iremod, which was independently developed by Simcere, will be the first Iguratimod drug on the global market. It is a new drug in the category of Disease Modifying Anti-rheumatic Drugs ("DMARDS"), and will be primarily used in the treatment of active rheumatoid arthritis. Clinical studies demonstrate that Iremod can significantly alleviate symptoms caused by active rheumatoid arthritis.

Mr. Ren Jinsheng, Chairman and Chief Executive Officer of Simcere, commented: "Bringing Iremod to the Chinese market will allow millions of patients suffering from active rheumatoid arthritis to enjoy higher quality treatment. Iremod will provide new and more effective options for doctors. This approval is a breakthrough for Simcere. We will continue to put our efforts and resources into developing and producing effective and innovative medicines for patients."

About Simcere Pharmaceutical GroupSimcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics. The Company has introduced an innovative anti-cancer medication Endu, first-to-market generics such as Bicun and Anxin, and a first-to-market medication Sinofuan. Simcere manufactures and sells drugs in the oncological, cardiovascular, anti-inflammatory and anti-infection therapeutical areas. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence or mortality rates and for which there is a clear demand for more effective pharmacotherapy including cancer and cardiovascular, cerebrovascular, inflammatory and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.Investor and Media Contacts: Email: ir@simcere.comIn Nanjing:Yehong ZhangPresidentSimcere Pharmaceutical GroupTel: +86-25-8556-6666 ext 8811In Beijing:Yue YuBrunswick Group Tel: +86-10-5960-8600In the United States:Kate TellierBrunswick GroupTel: +1-212-333-3810In Hong Kong:Joseph Lo Chi-LunBrunswick GroupTel: +852-3512-5000  
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... According to a new market research report "Sunitinib Malate ... Germany , France , U.K., ... Japan )", published by MarketsandMarkets, The market is projected to ... from 2016 to 2021.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302 ... through 26 Pages and in-depth TOC on "Sunitinib Malate ...
(Date:5/19/2016)... AVIV, Israel , May 19, 2016 ... or the "Company"), an emerging global ophthalmic company focused ... product candidates which address ophthalmic conditions, announced today that ... Italy ) for the manufacturing, distribution, ... product for the treatment of dry eye syndrome (DES) ...
(Date:5/19/2016)... May 19, 2016 At the 18 ... Meeting in Amsterdam , (May 15-19), Elekta ... clinically-proven radiosurgery system available, has been used in the ... brain tumors, vascular malformations and functional disorders. ... 75,000 patients every year in hundreds of leading hospitals ...
Breaking Medicine Technology:
(Date:5/24/2016)... VA (PRWEB) , ... May 24, 2016 , ... Controlling ... smarter - with the launch of the Aquanta Water Heater Controller , a ... smart phone or web-enabled device. As the Nest thermostat does for HVAC systems, ...
(Date:5/24/2016)... WI (PRWEB) , ... May 24, 2016 , ... ... In Milwaukee , Out patient Services To Begin In June , Aloria Health, ... pleased to announce the opening of Aloria Milwaukee, its first treatment facility for ...
(Date:5/24/2016)... NJ (PRWEB) , ... May 24, 2016 , ... The ... that’s causing the problem. A common injury that’s often misunderstood, whiplash should be swiftly ... MD, a Harvard-trained, orthopedic spine surgeon at Atlantic Spine Center . , ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... successful implementation of protocols designed to reduce bleeding complications from percutaneous coronary intervention ... Angiography and Interventions (SCAI) in Orlando, FL, document a 40% reduction in risk-adjusted ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... Essette Dashboard, its highly anticipated, web-based software module. The cutting-edge feature provides ... “secret sauce”? Integration with Izenda’s self-service business intelligence solution and its analytics ...
Breaking Medicine News(10 mins):